RAMAT HA SHARON, Israel, May 15, 2017 /PRNewswire/ -- Body Vision Medical, a medical device company specializing in augmented real-time imaging, announced today that it has received clearance from the U.S. Food and Drug Administration to market LungVision, a novel imaging system that enables accurate real-time navigation and lesion localization during bronchoscopic procedures.
LungVision, the first product based on the Body Vision platform, demonstrated outstanding results through multicenter clinical trials in the U.S. Utilizing a sophisticated augmented reality approach, LungVision allows physicians to plan, visualize, and track endobronchial tools and radiolucent lesions in real time. LungVision's synergistic imaging merges intraoperative fluoroscopy with pre-operative high resolution imaging, such as computed tomography.
"Body Vision developed unique technology that combines the intelligence of navigation with the simplicity of fluoroscopy," says D. Kyle Hogarth, MD, FCCP Associate Professor of Medicine, Director of Bronchoscopy at the University of Chicago and one of the first LungVision users in North America. "It enables effective localization and enhanced biopsy of lung lesions, upgrading the standard methods used in our daily practice."
Body Vision CEO Dorian Averbuch added, "We are thrilled to introduce the Body Vision platform to the medical community. We envision that in the near future, the LungVision system will revolutionize the way physicians diagnose and treat peripheral lung lesions."
The first clinical experience with the LungVision System will be presented by Sean Stoy, MD, University of Chicago Medical Center, at the American Thoracic Society meeting, held May 19-24 at the Walter E. Washington Convention Center in Washington, DC. The presentation will take place on May 21, 2017 from 2:15-4:15 pm as a part of the rapid poster discussion session A110, "Advances of the thoracic oncologic diagnostics".
About Body Vision Medical
Body Vision Medical is a medical device company specializing in augmented real-time imaging. The company was founded in 2014 to address the contemporary unmet clinical need of early lung cancer diagnostics and, in future, the growing demand of minimally invasive treatment. To learn more about the company visit us at www.bodyvisionmedical.com.
SOURCE Body Vision Medical